Arama Sonuçları - "press release"

Bayer registered a new indication for rivaroxaban for use in patients with coronary heart disease or peripheral artery disease in the European Union and USA Yazar: Bayer Company Press Release

Connect to this object online.

PREVENTION OF SEVERE INFECTIONS IN PATIENTS WITH GENETIC DISORDERS OF THE COMPLEMENT SYSTEM REGULATION TREATING WITH ECULIZUMAB: PRESS RELEASE ON THE INTERDISCIPLINARY EXPERT COUNCIL MEETING Yazar: Editorial article

Connect to this object online.

POST-EVENT PRESS RELEASE OF THE XXIII CONVENTION OF PEDIATRICIANS OF RUSSIA "ACTUAL PROBLEMS OF PEDIATRICS" ON THE TOPIC "PREVENTIVE VACCINATION OF PURULENT BACTERIAL MENINGITIS" Yazar: article Editorial

Connect to this object online.

PREVENTION OF SEVERE INFECTIONS IN PATIENTS WITH GENETIC DISORDERS OF THE COMPLEMENT SYSTEM REGULATION TREATING WITH ECULIZUMAB: PRESS RELEASE ON THE INTERDISCIPLINARY EXPERT COUNCIL MEETING Yazar: Editorial article

Connect to this object online.

Implementation of the scientifically recommended vaccine priority list <em>- A Press Release from the College of Community Physicians of Sri Lanka</em> Yazar: Co -Editors

Connect to this object online.

New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Yazar: Article Editorial

Connect to this object online.

New data from clinical practice again confirmed the high efficacy and a favorable safety profile of the drug Xarelto® in patients with atrial fibrillation (Press release of the company Bayer) Yazar: Article Editorial

Connect to this object online.

NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Yazar: article editorial

Connect to this object online.

NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY Yazar: article editorial

Connect to this object online.

Effective communications strategies to increase the impact of environmental health research Yazar: Rebecca E. Fuoco, Carol F. Kwiatkowski, Linda S. Birnbaum, Arlene Blum

Connect to this object online.

IХ NATIONAL CONGRESS ON INTERNAL MEDICINE

Connect to this object online.

CONFERENCE "GENETIC TESTING AS A SOCIAL RESPONSIBILITY OF CITIZENS AND A DISABILITY PREVENTION"

Connect to this object online.

IХ NATIONAL CONGRESS ON INTERNAL MEDICINE

Connect to this object online.

RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Yazar: . Editorial

Connect to this object online.

CONFERENCE "GENETIC TESTING AS A SOCIAL RESPONSIBILITY OF CITIZENS AND A DISABILITY PREVENTION"

Connect to this object online.

IХ NATIONAL CONGRESS ON INTERNAL MEDICINE

Connect to this object online.

DATA OF THE RECENTLY PUBLISHED SWISS STUDY SWIVTER (THE SWISS VENOUS THROMBOEMBOLISM REGISTRY) DEMONSTRATE THE REPRODUCIBILITY OF THE RESULTS OF RANDOMIZED TRIALS IN REAL CLINICAL... Yazar: статья Редкционная

Connect to this object online.

RIVAROXABAN OF THE BAYER COMPANY SIGNIFICANTLY (BY 24%) REDUCES THE RISK OF STROKE, CARDIOVASCULAR DEATH AND MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE O... Yazar: статья Редакционная

Connect to this object online.

CONFERENCE "GENETIC TESTING AS A SOCIAL RESPONSIBILITY OF CITIZENS AND A DISABILITY PREVENTION"

Connect to this object online.

RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY Yazar: . Editorial

Connect to this object online.